We combine patented intracellular analytics using DNA nanoprobes with AI to diagnose neurodegenerative diseases before symptoms manifest.
We combine patented intracellular analytics using DNA nanoprobes with AI to diagnose before symptoms manifest.
A paradigm shift in understanding how Alzheimer’s disease manifests opens up a whole new way of diagnosing, treating and managing the disease.
A paradigm shift in understanding how Alzheimer’s disease manifests opens up a whole new way of diagnosing, treating and managing the disease. We combine patented Intracellular Analytics with the use of DNA Nanoprobes and AI to diagnose Alzheimer’s desease before the symptoms manifest.
Our ratio-metric assays are exceptional in their ability to quantify the key chemicals within endosomes (early, recycling, and late), lysosomes, and the golgi. They can be used to complement drug discovery and patient stratification, as well as assess drug efficacy as an end point in clinical trials for lysosomal storage disorders and numerous neurocognitive impairments.
We are a start-up originally spun out of Dr. Yamuna Krishnan’s lab at the University of Chicago, now based across London, UK and the U.S.
Get in touch to discuss how our probes can help you with your work .
Esya is a dynamic company operating at the intersection of biochemistry, technology, and medicine. If you crave challenges and the chance to see your work impact the millions of lives touched by Alzheimer’s disease, there’s no better place to be.
We are a start-up originally spun out of Dr. Yamuna Krishnan’s lab at the University of Chicago, now based across London, UK, and the U.S.